Sana Shaikh
Nephrology · St Louis, MONPI 1619323888
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $624 of the $799 with a category attached, or 78.1%. 5 manufacturers reported payments, led by AstraZeneca at 29.2% of the total. 2025 is the largest year on record at $498, 3.6 times the $137 reported in 2019. That places this record below the midpoint for nephrology clinicians in MO, where the typical reported total is $723.
Across 8 payments — averaging $99.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$233
- Novartis$207
- Baxter Healthcare$137
- Apellis Pharmaceuticals, Inc.$115
- Bayer$105
Across 1 payment — averaging $48,400 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$48K
What the payments were for
- Consulting fees$17522%
- Food & beverage$62478%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 2 | $233 |
| Novartis | 2 | $207 |
| Baxter Healthcare | 2 | $137 |
| Apellis Pharmaceuticals, Inc. | 1 | $115 |
| Bayer | 1 | $105 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fabhalta$207
- ULTOMIRIS$175
- Renal - PD$112
- Kerendia$105
- Vanrafia$103
How this compares
$799 in reported general payments places this provider in the 50th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeltassaPatiromer Calcium Sorbitex | 26 | $25,139 |
| OzempicSemaglutide | 17 | $15,978 |
| Cinacalcet Hcl | 158 | $15,598 |
| Atovaquone | 30 | $15,490 |
| JardianceEmpagliflozin | 22 | $15,280 |
| EliquisApixaban | 15 | $8,798 |
| TradjentaLinagliptin | 17 | $7,801 |
| Valganciclovir Hcl | 40 | $4,111 |
| Pantoprazole Sodium | 130 | $830 |
| Fluconazole | 32 | $823 |
| Carvedilol | 97 | $341 |
| Potassium Chloride | 11 | $333 |
| Pravastatin Sodium | 84 | $271 |
| Tamsulosin Hcl | 33 | $270 |
| Famotidine | 71 | $243 |
Paid to pharmacies, not to this prescriber.
Other nephrology in St Louis
- Kevin MartinSt Louis$189K
- Bahar BastaniSt Louis$87K
- Nicholas GourtzelisSt Louis$9K
- Derek LarsonCreve Coeur$605K
- Marcos RothsteinSaint Louis$350K
- Anuja JavaSaint Louis$240K
- Alejandro AlvarezFlorissant$176K
- Gary SingerSaint Peters$170K
- Daniel CoyneSaint Louis$163K
- Tarek AlhamadSaint Louis$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.